MD Anderson Ovarian Cancer Program
The University of Texas MD Anderson Cancer Center SPORE in Ovarian Cancer
Testing new treatment strategies to help people with ovarian cancer whose disease is resistant to chemotherapy, PARP inhibitors, anti‑angiogenic drugs, or immunotherapy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11159399 on NIH RePORTER |
What this research studies
This program develops and brings new therapies to people with ovarian cancer, focusing on overcoming treatment resistance to chemotherapy, PARP inhibitors, anti‑angiogenic agents (like bevacizumab), and immune checkpoint drugs. Researchers run clinical trials at MD Anderson, collect tumor and blood samples, and use biomarker and algorithm work to improve early detection and match patients to treatments. The project also supports translation of lab findings into clinical options and builds investigator training and recruitment to speed trials. Past SPORE work at MD Anderson has produced screening advances and new biomarkers that inform their ongoing clinical efforts.
Who could benefit from this research
Good fit: People diagnosed with ovarian cancer, especially those with recurrent or treatment‑resistant disease and those able to enroll in clinical trials at MD Anderson, are the ideal candidates.
Not a fit: People without ovarian cancer, those who cannot travel to Houston for visits, or those who do not meet specific trial eligibility criteria are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the program could produce treatments and tests that work when current therapies stop working and help detect some ovarian cancers earlier.
How similar studies have performed: Related approaches at MD Anderson have shown promise, including improved early detection in prior SPORE-supported studies and identification of new biomarkers, though many strategies remain experimental.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Sood, Anil K — University of Tx Md Anderson Can Ctr
- Study coordinator: Sood, Anil K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.